PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25077812-3 2015 CYP2C9 and CYP2E1 specifically metabolised sulfonylurea herbicides and halogenated hydrocarbons respectively. Sulfonylurea Compounds 43-55 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 26802434-4 2016 The field of pharmacogenetics is now yielding clinically important results, with three examples outlined: sulphonylurea sensitivity in patients with HNF1A maturity-onset diabetes of the young; sulphonylurea sensitivity in patients with Type 2 diabetes with reduced function alleles at CYP2C9, resulting in reduced metabolism of sulphonylureas; and severe metformin intolerance associated with reduced function organic cation transporter 1 (OCT1) variants, exacerbated by drugs that also inhibit OCT1. Sulfonylurea Compounds 193-206 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 285-291 27180666-4 2016 The response to sulfonylurea derivatives was significantly associated with the variants KCNJ11/ABCC8, TCF7L2 and CYP2C9. Sulfonylurea Compounds 16-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 113-119 24590592-9 2014 Since other sulfonylureas in clinical use are substrates of CYP2C9, their hepatic CLint changes have the potential to cause clinically relevant pharmacokinetic changes in a hyperlipidemic state. Sulfonylurea Compounds 12-25 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 60-66 24464600-0 2014 CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Sulfonylurea Compounds 98-111 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 24464600-10 2014 Therefore, POR*28 allele is an important source of CYP2C9 activity variability and combined with CYP2C9 gene poly-morphisms may explain individual variability in the effect of sulfonylureas. Sulfonylurea Compounds 176-189 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 97-103 24464600-1 2014 It is previously shown that carriers of the defective allele CYP2C9*3 that leads to impaired sulfonylurea metabolism are at increased sulfonylurea-induced hypoglycemia risk due to diminished drug metabolism, whereas no effect of CYP2C9*2 allele was found. Sulfonylurea Compounds 93-105 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 61-67 24464600-8 2014 In a model adjusted for age, BMI, duration of T2DM and renal function, and POR*1/*1 entered as a selection variable, CYP2C9*2 allele increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 3.218, p=0.031). Sulfonylurea Compounds 180-192 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 117-123 24464600-9 2014 In conclusion, our results suggest that POR*28 allele is masking the association of CYP2C9*2 allele with sulfonyl-urea-induced hypoglycemia. Sulfonylurea Compounds 105-118 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 84-90 20698928-5 2010 RESULTS: Almost 20% of patients were exposed to a potential drug-drug interaction with a CYP2C9 inhibitor during sulphonylurea treatment. Sulfonylurea Compounds 113-126 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 24324494-3 2013 The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. Sulfonylurea Compounds 89-102 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 21-27 24324494-4 2013 CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K(+) channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. Sulfonylurea Compounds 15-27 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 24324494-4 2013 CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K(+) channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. Sulfonylurea Compounds 185-198 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 21121772-0 2010 Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Sulfonylurea Compounds 77-90 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 21121772-1 2010 AIMS: Sulfonylureas are mainly metabolized by the enzyme CYP2C9. Sulfonylurea Compounds 6-19 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 57-63 21121772-2 2010 Two allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been associated with elevated sulfonylurea serum levels. Sulfonylurea Compounds 123-135 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 22-28 21121772-2 2010 Two allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been associated with elevated sulfonylurea serum levels. Sulfonylurea Compounds 123-135 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 35-41 21121772-4 2010 In this study, the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of sulfonylureas was investigated. Sulfonylurea Compounds 105-118 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 29-35 21121772-4 2010 In this study, the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of sulfonylureas was investigated. Sulfonylurea Compounds 105-118 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 23588782-15 2013 CYP2C9 is responsible for metabolising vitamin K antagonists (VKAs), non-steroidal anti-inflammatory drugs (NSAIDs), sulfonylureas, angiotensin II receptor antagonists and phenytoin. Sulfonylurea Compounds 117-130 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 23588782-19 2013 A relationship between CYP2C9 polymorphisms and the pharmacokinetics of sulfonylureas and angiotensin II receptor antagonists has also been observed. Sulfonylurea Compounds 72-85 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 23-29 23153186-2 2012 AREAS COVERED: This review focuses on the effect of CYP2C enzymes on metabolism of sulphonylureas (SUs), meglitinides, and thiazolidinediones (TZDs) discussing their impact on pharmacokinetics, drug interactions and toxicological profiles. Sulfonylurea Compounds 83-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-57 23153186-2 2012 AREAS COVERED: This review focuses on the effect of CYP2C enzymes on metabolism of sulphonylureas (SUs), meglitinides, and thiazolidinediones (TZDs) discussing their impact on pharmacokinetics, drug interactions and toxicological profiles. Sulfonylurea Compounds 99-102 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-57 23153186-4 2012 EXPERT OPINION: Genetic polymorphisms of CYP2C9 enzymes (*2/*2, *2/*3, *3/*3) influence the glycaemic response to SUs and impair their substrate metabolism. Sulfonylurea Compounds 114-117 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 41-47 21939641-3 2011 In this brief review, we discussed the impact of CYP2C polymorphisms on the metabolic fate of small-molecule antidiabetics including sulfonylureas, meglitinides, thiazolidinediones, gliptins, and gliflozins, with the key drug-protein molecular interactions highlighted. Sulfonylurea Compounds 133-146 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-54 21356265-1 2011 Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Sulfonylurea Compounds 8-21 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 132-138 21213107-2 2011 As the genetically polymorphic cytochrome P450 (CYP), enzyme CYP2C9 is mainly responsible for the hepatic metabolism of sulfonylureas (SUs), we hypothesized that the slow-metabolizer genotypes *2/*2, *2/*3, and *3/*3 might be overrepresented in type 2 diabetic patients with SH. Sulfonylurea Compounds 120-133 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 61-67 21213107-2 2011 As the genetically polymorphic cytochrome P450 (CYP), enzyme CYP2C9 is mainly responsible for the hepatic metabolism of sulfonylureas (SUs), we hypothesized that the slow-metabolizer genotypes *2/*2, *2/*3, and *3/*3 might be overrepresented in type 2 diabetic patients with SH. Sulfonylurea Compounds 135-138 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 61-67 21213107-9 2011 However, in the control group, patients with CYP2C9 genotypes, predicting slower metabolism of SU drugs, were treated with significantly lower doses (p = 0.027) than were extensive metabolizers, whereas in the patient group with severe hypoglycemia, the dose was the same for all genotype groups. Sulfonylurea Compounds 95-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 21142408-2 2011 Both clopidogrel and the oral hypoglycemic drug class sulfonylureas are metabolized by the iso-enzyme CYP2C9. Sulfonylurea Compounds 54-67 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 102-108 20698928-10 2010 CONCLUSIONS: Concomitant use of a CYP2C9 inhibitor results in exaggerated pharmacodynamic effects of sulphonylureas and increases the risk of hypoglycaemia in T2DM patients receiving glibenclamide, glimepiride or glipizide. Sulfonylurea Compounds 101-115 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 19794412-0 2010 Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Sulfonylurea Compounds 65-78 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 17-23 20222813-4 2010 In this article, we review a study examining the association of genetic variation in the cytochrome P450 2C9 enzyme with glycemic response to sulfonylureas in a large cohort of patients with Type 2 diabetes from the Genetics of Diabetes Audit and Research Tayside Study (Go-DARTS). Sulfonylurea Compounds 142-155 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-108 19794412-1 2010 Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 44-63 19794412-1 2010 Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 65-71 19794412-7 2010 In conclusion, CYP2C9 loss-of-function alleles are associated with greater response to sulfonylureas and decreased failure of therapy consistent with the pharmacokinetic role of CYP2C9. Sulfonylurea Compounds 87-100 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 15-21 17963417-6 2007 Multiple studies indicated that the CYP2C9 *3 allele (Ile359Leu polymorphism) was associated with decreased clearance of sulfonylurea drugs. Sulfonylurea Compounds 121-133 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 36-42 19891554-0 2009 Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Sulfonylurea Compounds 101-114 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 12-18 19891554-2 2009 Impaired metabolism of sulfonylureas due to gene polymorphisms in the metabolic enzyme CYP2C9 might lead to hypoglycemia. Sulfonylurea Compounds 23-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 87-93 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. Sulfonylurea Compounds 178-191 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. Sulfonylurea Compounds 178-191 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-85 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. Sulfonylurea Compounds 178-191 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-85 19891554-9 2009 In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011). Sulfonylurea Compounds 53-65 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 19891554-9 2009 In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011). Sulfonylurea Compounds 172-184 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 19891554-12 2009 Furthermore, in T2DM patients, CYP2C9*3 increases the risk of hypoglycemia when they are treated with sulfonylureas, possibly due to impaired metabolism of these drugs. Sulfonylurea Compounds 102-115 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 31-37 19891554-13 2009 CYP2C9 genotyping might thus be a useful tool for predicting adverse effects caused by sulfonylureas and help clinicians in safer prescribing of oral hypoglycemic agents. Sulfonylurea Compounds 87-100 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 17597710-1 2008 Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 57-76 17597710-1 2008 Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 78-84 18503607-3 2008 Glyburide, a sulphonylurea, is an insulin sensitizer and mainly metabolized by CYP2C9. Sulfonylurea Compounds 13-26 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-85 16372821-6 2005 Total oral clearance of all studied sulphonylureas (tolbutamide, glibenclamide [glyburide], glimepiride, glipizide) was only about 20% in persons with the CYP2C9*3/*3 genotype compared with carriers of the wild-type genotype CYP2C9*1/*1, and clearance in the heterozygous carriers was between 50% and 80% of that of the wild-type genotypes. Sulfonylurea Compounds 36-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 155-161 15963101-0 2005 Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Sulfonylurea Compounds 98-111 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 20-26 15963101-1 2005 AIMS: The genetically polymorphic cytochrome P450 (CYP) enzyme CYP2C9 metabolizes most sulphonylurea oral hypoglycaemic agents. Sulfonylurea Compounds 87-100 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 63-69 15660356-3 2005 The transgenic rice plant 2C9-57R2 expressing CYP2C9 gene showed resistance to sulfonylureas, and the transgenic rice plant 2C19-12R1 expressing CYP2C19 gene showed cross-resistance to certain herbicides with different structures and modes of action. Sulfonylurea Compounds 79-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 12405866-17 2002 Sulfonylurea drugs utilise mainly CYP2C9 for metabolism, and this isoenzyme may be induced by ritonavir and nelfinavir with a resulting decrease in efficacy of the sulfonylurea. Sulfonylurea Compounds 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 15349140-5 2004 In addition, multiple human studies have demonstrated significant associations between CYP2C9 genotype and the disposition of substrates such as warfarin, phenytoin and various sulfonylureas, angiotensin II receptor blockers and non-steroidal antiinflammatory agents. Sulfonylurea Compounds 177-190 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 87-93 12405866-17 2002 Sulfonylurea drugs utilise mainly CYP2C9 for metabolism, and this isoenzyme may be induced by ritonavir and nelfinavir with a resulting decrease in efficacy of the sulfonylurea. Sulfonylurea Compounds 164-176 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 33840516-0 2021 Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis. Sulfonylurea Compounds 103-115 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 24-30 34900803-0 2021 A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients. Sulfonylurea Compounds 67-80 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 33-39 34900803-2 2021 Sulfonylureas (SFUs) are the most widely used among the oral antidiabetic drugs that are highly metabolized by cytochrome P450 family 2 subfamily C member 9 (CYP2C9). Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-156 34900803-2 2021 Sulfonylureas (SFUs) are the most widely used among the oral antidiabetic drugs that are highly metabolized by cytochrome P450 family 2 subfamily C member 9 (CYP2C9). Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 158-164 34900803-2 2021 Sulfonylureas (SFUs) are the most widely used among the oral antidiabetic drugs that are highly metabolized by cytochrome P450 family 2 subfamily C member 9 (CYP2C9). Sulfonylurea Compounds 15-19 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-156 34900803-2 2021 Sulfonylureas (SFUs) are the most widely used among the oral antidiabetic drugs that are highly metabolized by cytochrome P450 family 2 subfamily C member 9 (CYP2C9). Sulfonylurea Compounds 15-19 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 158-164 34429480-1 2021 CYP2C9, one of the most abundant hepatic cytochrome P450 enzymes, is involved in metabolism of 15-20% of clinically important drugs (warfarin, sulfonylureas, phenytoin, non-steroid anti-inflammatory drugs). Sulfonylurea Compounds 143-156 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 34656068-1 2022 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 53-72 34656068-1 2022 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds 0-13 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 74-80 34656068-1 2022 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds 15-18 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 53-72 34656068-1 2022 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds 15-18 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 74-80 34656068-2 2022 CYP2C9 polymorphisms are associated with greater treatment response and hypoglycemic risk in SU users. Sulfonylurea Compounds 93-95 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 34194474-11 2021 The CYP2C9 alleles, * 2 (rs1799853C>T) and * 3 (rs1057910A>C) that are predictive of low enzyme activity were more common in subjects who experienced hypoglycemia after treatment with sulfonylureas. Sulfonylurea Compounds 184-197 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 4-10 33840516-2 2021 Because impaired catalytic function is likely to affect sulfonylurea metabolism, it is predictable that CYP2C9 loss-of-function alleles may increase the risk of sulfonylurea-induced hypoglycemia. Sulfonylurea Compounds 56-68 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 33840516-2 2021 Because impaired catalytic function is likely to affect sulfonylurea metabolism, it is predictable that CYP2C9 loss-of-function alleles may increase the risk of sulfonylurea-induced hypoglycemia. Sulfonylurea Compounds 161-173 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 33840516-3 2021 This systematic review and meta-analysis aimed to assess the association between CYP2C9 genotype and hypoglycemia among patients with type 2 diabetes mellitus (T2DM) receiving sulfonylurea. Sulfonylurea Compounds 176-188 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 81-87 33840516-4 2021 METHODS: We searched for studies on the association between CYP2C9 genotype and sulfonylurea-induced hypoglycemia among patients with T2DM, published through August 7, 2020, using PubMed, Web of Science, and EMBASE. Sulfonylurea Compounds 80-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 60-66 33840516-7 2021 The CYP2C9 variant alleles were associated with an increase in sulfonylurea-induced hypoglycemia compared with wild-type homozygote (OR = 1.24; 95% CI, 1.03-1.48). Sulfonylurea Compounds 63-75 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 4-10 33840516-9 2021 IMPLICATIONS: On the basis of these results, CYP2C9 genotyping may be useful for predicting the risk of hypoglycemia during sulfonylurea treatment for T2DM. Sulfonylurea Compounds 124-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 33612460-0 2020 Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy. Sulfonylurea Compounds 20-32 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 31709648-9 2020 Further studies are needed to clarify the utility of CYP2C9 genotyping to guide sulfonylurea treatment. Sulfonylurea Compounds 80-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 53-59 32504053-3 2020 In a retrospective case-control study in European American patients with T2DM, we examined the potential association between CYP2C9 reduced-function variants and sulfonylurea-related hypoglycemia. Sulfonylurea Compounds 162-174 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 125-131 32606720-10 2020 The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. Sulfonylurea Compounds 50-63 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148 33731883-4 2021 Genetic polymorphisms of CYP2C9, the main enzyme involved in the metabolism of sulfonylureas, have been associated with the risk of severe hypoglycaemia, particularly in poor metabolizers carrying CYP2C9 *3/*3 genotype, and especially in the case of patients treated with glimepiride. Sulfonylurea Compounds 79-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 25-31 33731883-4 2021 Genetic polymorphisms of CYP2C9, the main enzyme involved in the metabolism of sulfonylureas, have been associated with the risk of severe hypoglycaemia, particularly in poor metabolizers carrying CYP2C9 *3/*3 genotype, and especially in the case of patients treated with glimepiride. Sulfonylurea Compounds 79-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 197-203 32575674-0 2020 rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. Sulfonylurea Compounds 130-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 32575674-11 2020 CONCLUSION: The combination of metformin/sulfonylurea therapy led to the maximum glycemic control in individuals with T2DM carrying AA or AC genotypes in SLC22A1 and *1*3 in CYP2C9. Sulfonylurea Compounds 41-53 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 174-180 32606720-0 2020 The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. Sulfonylurea Compounds 98-111 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 14-20 32406758-3 2020 CYP2C9 is one of the most abundant CYP enzymes and responsible for the metabolism of over 15% clinical drugs, including oral sulfonylurea hypoglycemics, nonsteroidal anti-inflammatory agents, selective cyclooxygenase-2 inhibitors, antiepileptics, angiotensin II receptor inhibitors and anticoagulants. Sulfonylurea Compounds 125-137 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 33612460-0 2020 Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy. Sulfonylurea Compounds 20-32 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 33612460-0 2020 Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy. Sulfonylurea Compounds 20-32 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 33612460-1 2020 CYP2C9 is an important member of the cytochrome P450 gene family involved in the metabolism of 15% of the drugs including an oral antidiabetic agent sulfonylurea. Sulfonylurea Compounds 149-161 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 33612460-2 2020 This study aims to investigate the frequency of CYP2C9*2 and CYP2C9*3 alleles of the gene in the sulfonylurea treated diabetic subjects in Pakistan. Sulfonylurea Compounds 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 33612460-2 2020 This study aims to investigate the frequency of CYP2C9*2 and CYP2C9*3 alleles of the gene in the sulfonylurea treated diabetic subjects in Pakistan. Sulfonylurea Compounds 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 61-67 27958378-4 2018 In ancestry-specific meta-analyses, eight novel pharmacogenomic loci met the threshold for genome-wide significance (P<5 x 10-8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated with sulfonylurea-related treatment effects and other adverse drug reactions in previous studies was replicated. Sulfonylurea Compounds 215-227 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 166-172 31086662-1 2019 The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed sulphonylureas (SUs), which are metabolized by cytochrome P450 2C9 (abbreviated as CYP2C9). Sulfonylurea Compounds 114-117 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 145-164 31086662-1 2019 The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed sulphonylureas (SUs), which are metabolized by cytochrome P450 2C9 (abbreviated as CYP2C9). Sulfonylurea Compounds 114-117 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 181-187 28656666-1 2018 Data on the association of CYP2C9 genetic polymorphisms with sulfonylurea (SU)-induced hypoglycaemia (SH) are inconsistent. Sulfonylurea Compounds 61-73 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 27-33 28656666-1 2018 Data on the association of CYP2C9 genetic polymorphisms with sulfonylurea (SU)-induced hypoglycaemia (SH) are inconsistent. Sulfonylurea Compounds 75-77 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 27-33 28656666-6 2018 The number of CYP2C9 deficient alleles was associated with nearly three-fold higher odds of hypoglycaemia (OR, 2.81; 95% CI, 1.30-6.09; P = .009) and better response to SU treatment (beta, -0.218; SE, 0.074; P = .003) only in patients carrying the POR*1/*1 genotype. Sulfonylurea Compounds 169-171 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 14-20 28656666-7 2018 Our results indicate that interaction between CYP2C9 and POR genes may be an important determinant of efficacy and severe adverse effects of SU treatment. Sulfonylurea Compounds 141-143 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 27885968-0 2016 Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia. Sulfonylurea Compounds 53-66 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 23-29 27885968-1 2016 AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. Sulfonylurea Compounds 58-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 36-42 27885968-1 2016 AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. Sulfonylurea Compounds 73-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 36-42 27885968-2 2016 MATERIALS & METHODS: We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. Sulfonylurea Compounds 83-86 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 108-114 27885968-6 2016 CONCLUSION: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians. Sulfonylurea Compounds 91-94 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 71-77 27885968-6 2016 CONCLUSION: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians. Sulfonylurea Compounds 91-94 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 168-174 27885968-6 2016 CONCLUSION: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians. Sulfonylurea Compounds 182-185 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 71-77 27885968-6 2016 CONCLUSION: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians. Sulfonylurea Compounds 182-185 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 168-174